Opinion|Videos|May 12, 2025
Comparing Trials Studying Treatment Intensification In mHSPC
Author(s)Neal Shore, MD, FACS
A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, and LATITUDE while highlighting the nuanced differences in adverse effect profiles and tolerability among these agents.
Advertisement
Episodes in this series
Comparative Analysis With Other mHSPC Trials
Key Themes:
- Comparison between ARANOTE and other intensification trials (ARCHES, TITAN, LATITUDE)
- Differences in patient populations and trial design
- Unique attributes of various androgen receptor pathway inhibitors
Expert Insights:
- Dr Shore compared darolutamide's performance in ARANOTE to other agents: enzalutamide (ARCHES), apalutamide (TITAN), and abiraterone (LATITUDE).
While all agents demonstrated benefit when combined with androgen deprivation therapy, Dr Shore noted important differences in adverse effect profiles, tolerability, and patterns of adoption in clinical practice.
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
4
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
5